PRESS RELEASE
Uppsala
January 7, 2009

Q-Med has obtained registration approval for Restylane® in China

Q-Med has obtained registration approval for Restylane® in China. An application for sales approval will be submitted shortly and it is estimated that sales of the product will begin at the end of the second quarter in 2009.

"There is a large appetite for new things in China and great respect for products from the West. We are therefore very pleased about this registration approval, which means that Restylane® will be the first hyaluronic acid product intended for the cosmetic market in China", says Bengt Ågerup, Q-Med´s President and CEO.

Queries should be addressed to:

Bengt Ågerup, President and CEO
Tel: +46 (0)70 974 9025
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70 974 9015

__Q-Med AB__ is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, __NASHA™__, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: __Restylane®__ for filling lines and folds, contouring and creating volume in the face, __Macrolane™__ for body contouring, __Durolane™__ for the treatment of osteoarthritis of the hip and knee joints, __Deflux®__ for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and __Solesta™__ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
